Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Investor Eye: What's Changing In Medtech Deal Making As We Approach The End Of 2022?

Executive Summary

Kristen Pothier, global lead of KPMG’s health care and life sciences advisory service, spoke to Medtech Insight about the current deal making climate, and how it impacts the diagnostics sector.

You may also be interested in...



Deerfield Management On Fund Building, Philanthropy, And Optimism For The Future

Andrew ElBardissi, partner on Deerfield Management’s medical technologies team, spoke to In Vivo sister publication Medtech Insight about the fund’s investment strategy, the changing face of medtech, and how investment in the life sciences sector will continue to change post-COVID.

Investor Eye: Deerfield Management On Fund Building, Philanthropy, And Optimism For The Future

Andrew ElBardissi, partner on Deerfield Management’s medical technologies team, spoke to Medtech Insight about the fund’s investment strategy, the changing face of medtech, and how investment in the life sciences sector will continue to change post-COVID.

Liquid Biopsy Revolutionizing Cancer Care, But Costs Continue To Inhibit Global Potential

Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT145748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel